Skip to main content

Featured Studies

Office of Patient Recruitment

This web page makes it easy to search for featured research studies at the NIH Clinical Center. You can search for specific studies by entering keywords related to your symptoms in the search box or by using the sort and filter options.


To view a full list of all studies conducted at the NIH Clinical Center, visit Search the Studies.

Filter By

Visit Type

Patient or Healthy Volunteer

Age Group

Institution

Web Page Language

Reset All Filters
3 results
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus

People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. The risks increase for heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Researchers at NIH are testing whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with (SLE). Participants do not pay for tests, treatments, or procedures.
Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 000682-AR.
Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer

Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer.

Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 21-DC-0002.
Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer

Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer (En español)

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer. (En español)

Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 21-DC-0002.
Was this page helpful?